Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s leadership has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare conditions.
For more information on Amplyx, please visit our website at www.amplyx.com
Location: United States, California, San Diego
Employees: 11-50
Total raised: $207.7M
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors | Deal News |
| 20.05.2020 | Series C | $90M | Sofinnova ... | finsmes.co... |
| 02.08.2017 | Series C | $67M | New Enterp... | socaltech.... |
| 09.02.2016 | - | $8.7M | - | finsmes.co... |
| 11.11.2015 | Series B | $40.5M | - | finsmes.co... |
| 09.04.2010 | - | $1.5M | - | socaltech.... |
Mentions in press and media 23
| Date | Title | Description | Source |
| 03.12.2020 | Amplyx Announces Upcoming Virtual Data Presentations at 62nd... | SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical... | prnewswire... |
| 06.11.2020 | Covid-19 roundup: Novartis treatment comes up short in Ph... | A major player trying to adapt an anti-inflammatory for Covid-19 has seen the drug fall flat... | endpts.com... |
| 20.05.2020 | Amplyx closes $53 million Series C extension | - | arixbiosci... |
| 19.05.2020 | Amplyx Pharmaceuticals Adds $53M In Funding | San Diego-based Amplyx Pharmaceuticals has raised $53M in a Series C extension funding, bringing its... | socaltech.... |
| 19.05.2020 | Amplyx Pharmaceuticals Closes $53M Series C Extension | Amplyx Pharmaceuticals, a San Diego, CA-based biotech company developing innovative therapies for de... | finsmes.co... |
| 19.05.2020 | Immune Therapeutics Company Amplyx Pharmaceuticals Adds $53M... | - | connect.or... |
| 17.09.2019 | Amgen inks discovery deal with Hummingbird; Merck gain... | → Amgen has enlisted Hummingbird Bioscience on a new antibody discovery pact, turning ove... | endpts.com... |
| 03.08.2017 | Term Sheet — Thursday, Aug. 3 | MARKDOWNS AGAIN After we wrote about mutual fund markdowns to Uber’s share price, a few readers wro... | fortune.co... |
| 02.08.2017 | Amplyx Pharmaceuticals Gets $67M | San Diego-based Amplyx Pharmaceuticals, which develops antifungal agents aimed at treating fungal in... | socaltech.... |
| 02.08.2017 | Amplyx Pharmaceuticals Inks $67M in Series C | SAN DIEGO, CA, Company developing novel antifungal agents for life-threatening fungal infections, ... | vcnewsdail... |
Show more